Type in a keyword and see the report right away. Explore your online world!
If you have already a Newsmeter account:
You can free sign up for Newsmeter:
x
The Ambulatory Specialty Model aims to reduce chronic disease costs by mandating specialist participation and tying payments to quality and cost, while posing nationwide risk challenges.
SGLT2 inhibitors have outgrown their diabetes-only label, and formulary teams that still price them that way are missing the bigger cardiorenal picture entirely.
Cost data in AATD depend heavily on how patients are identified. Augmentation therapy adds a substantial burden, yet survival benefit and comorbidity management complicate any simple cost comparison for payers.
Clinicians cannot be expected to remember every rare disease. Default order sets, testing tied to pulmonary function results, and standardized genotyping can make AATD testing the easy choice rather than an added burden.
Cleveland Clinic's Beth Faiman, PhD, MSN, discusses advanced practitioners' reimbursement and how outpatient trispecific antibodies could increase access.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Separate risk systems now guide intensive and lower-intensity AML therapy, and objective fitness criteria are replacing the eyeball test in deciding which patients should receive which approach.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
ApoB more directly reflects atherogenic particle burden than LDL-C, but missing outcome trials and assay variability still limit its routine use.
The ADRIATIC trial reshaped limited-stage treatment, extending median survival by nearly two years with consolidation immunotherapy, a shift so significant that adherence, not efficacy, is now the field's central clinical challenge.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Cleveland roundtable panelists across 4 disease states name access, not evidence, as the shared barrier to care.
